| Revenue growth | Consolidated revenue up 17% YoY to ₹271.5 billion. |
|---|---|
| Margins | Record 31.2% EBITDA margin, 80 bps improvement YoY. |
| Demand visibility | Strong demand in India branded formulations and US specialty segments. |
| Management confidence | Extremely high following record margins and successful inorganic expansions. |
Growth
Double-digit organic growth across India and US markets, propelled by specialty launches and volume expansion in generic segments.
Outlook
Guided high-teens revenue growth for FY27 with EBITDA margins exceeding 24% despite heavy investment phases.
Risks
High base effect for FY27, increased competition in Revlimid, and rising R&D/commercialization costs for new launches.
Earnings Call filed with BSE, NSE: ZYDUSLIFE. Summary written with AI assistance from the document.
Zydus Lifesciences Ltd: key numbers
- Share price
- ₹1,203.90
- Market cap
- ₹1,21,141 Cr
- Revenue (annual)
- ₹27,148 Cr
- Net profit (annual)
- ₹5,040 Cr
- P/E (TTM)
- 26.8×Sector 50.4×
- Promoter holding
- 75.01%+0.01% QoQ
- FII holding
- 6.89%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Zydus Lifesciences Ltd
All →Zydus Lifesciences Business Update
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
Zydus Lifesciences Credit Rating
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences Legal & Regulatory
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
- Value
- ₹55.46 Cr
Zydus Lifesciences Earnings Call Transcript: Key Takeaways
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
- Call
- Guides 10% growth
Zydus Lifesciences Investor Presentation: Key Takeaways
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Q1 FY27 Results: Net Profit ₹939.8 Cr, Down 35.9% YoY
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.
- Key figure
- Net profit ₹939.8 Cr · -35.9% YoY